RUKOBIA, in combination with other antiretrovirals (ARVs), is indicated to treat HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current ARV regimen due to resistance, intolerance, or safety considerations.
*Prevents HIV-1 from interacting with host immune cells by binding gp120, leaving CD4+ T-cells untouched.
AND IT MAY GIVE PATIENTS WITH LIMITED OPTIONS THEIR NEXT OPTION
GIVE PATIENTS WITH LIMITED OPTIONS THEIR NEXT OPTION
AE=adverse event; BID=twice daily; gp120=glycoprotein 120; HIV-1=human immunodeficiency virus type 1; IRIS=immune reconstitution inflammatory syndrome; MDR=multidrug-resistant; MOA=mechanism of action.
Sign Up for our next webinar
Listen to Edge of Yesterday:
A Podcast Series by ViiV Healthcare
- Aberg J, Shephard B, Wang, et al. Efficacy and safety of fostemsavir plus optimized background therapy in heavily treated-experienced adults with HIV-1: Week 240 results of the Phase 3 BRIGHTE study. Poster EPB160. Poster presented at; 24th International AIDS Conference; July 29-August 2, 2022; Montreal, Canada.
- Data on file ViiV Healthcare.
- Lataillade M, Lalezari JP, Kozal M, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. Lancet HIV. 2020;7(11):740-751.
- Gartland M, et al. J Antimicrob Chemother. 2021;76(3):648-652.